Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Tuvusertib (M1774) in Participants with Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
Merck Sharp and Dohme
Metastatic or Locally Advanced Unresectable Solid Tumors
1 trial -
CAPECITABINE, CALCIUM FOLINATE, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Calciumfolinat Kabi 10 mg/ml Injektions-/Infusionslösung, FLUOROURACIL, Lenvatinib, Lenvatinib, Calciumfolinat-GRY® 100 mg/10 ml Injektionslösung, OXALIPLATIN, Lenvatinib, CALCIUM LEVOFOLINATE , CAPECITABINE
Merck Sharp and Dohme
Advanced/Metastatic Gastroesophageal Adenocarcinoma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources